Gilead/Galapagos' Trailing JAK1 Filgotinib Boosted By AS Trial
Gilead and Galapagos have more decent clinical data for filgotinib tucked under their belt as the JAK1 inhibitor shows benefit in another indication, ankylosing spondylitis, with a safety profile that remains reassuring.
You may also be interested in...
Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.
Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.
Prospects rose for Galapagos and partner Gilead's JAK1 inhibitor with impressive Phase III FINCH 2 data in patients with moderate-to-severe rheumatoid arthritis.